An article has been published in the Journal of Laboratory Medicine highlighting the importance of hemolysis detection in blood gas analysis as well that Hemcheck has a solution for this issue. Authors are Martin Möckel, professor and specialist in acute medicine at the university hospital Charité in Berlin and Peter Luppa, professor and specialist in laboratory medicine at the university hospital TUM in Münich.

-This type of independent articles that highlights the issues with hemolysis and the importance of patient near hemolysis detection is very important for Hemcheck. The authors are well renowned and the fact that they also highlight Hemcheck is very good for us and can give us more international exposure and marketing, says Joen Averstad, CEO of Hemcheck.

Link to the article: https://www.degruyter.com/document/doi/10.1515/labmed-2021-0076/html

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com 

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.